Ulaner et al. (2020) were also able to apply 89Zr-Pertuzumab PET/CT to facilitate the successful detection of HER2-positive metastatic lesions in patients with biopsy-confirmed HER2-negative primary breast tumors. This evidence concerns the gene ERBB2 and breast neoplasm.